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Abstract
 .A male child with metabolic acidosis was diagnosed as having dihydrolipoamide dehydrognase E3 deficiency. E3
activity of the proband’s cultured fibroblasts and blood lymphocytes was 3–9% of normal, while in the parent’s
 .lymphocytes it was about 60% of normal. The proband’s pyruvate dehydrogenase complex PDC and the a-ketoglutarate
dehydrogenase complex activities from cultured skin fibroblasts were 12% and 6% of normal, respectively. PDC activity in
the parents cultured fibroblasts was 25–31% of normal. Western and Northern blot analyses showed similar quantities of E3
protein and mRNA in cultured fibroblasts from the proband and his parents. DNA sequencing of cloned full-length E3
cDNAs, from the proband and the parents, showed two mutations on different alleles of proband were inherited from the
 .parents. One mutation is a three nucleotide AGG deletion, from the mother, resulting in deletion of Gly101 in the FAD
 .binding domain. The other mutation is a nucleotide substitution G to A , from the father, leading to substitution of Lys for
Glu340 in the central domain. The same deletion mutation was found in E3 cDNA from a chorionic villus sample and
cultured fibroblasts obtained from the mother’s subsequent offspring. This finding illustrates the possiblilty of successful
prenatal diagnosis of E3 deficiency utilizing mutations characterized prior to initiation of pregnancy. q 1997 Elsevier
Science B.V.
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1. Introduction
Mammalian dihydrolipoamide dehydrogenase E3,
q .dihydrolipoamide:NAD oxidoreductase, EC 1.8.1.4
is the common flavoprotein component of the three
a-keto acid dehydrogenase multienzyme complexes,
 .pyruvate dehydrogenase complex PDC , a-keto-
 .glutarate dehydrogenase complex KGDC , and
branched-chain a-keto acid dehydrogenase complex
 . w x BCKDC 1 . E3 is also a component known as the
. w xL protein of the glycine cleavage system 2 . The
human E3 gene is located on chromosome 7, within
w xbands q31–q32 3 . This gene encodes a 509 amino
acid protein, of which the N-terminal 35 amino acids
form a leader sequence having an a-helical structure
w xthat is cleaved during import into mitochondria 4 .
The active enzyme is a homodimer of 51 kDa sub-
units with 4 distinctive subdomain structures FAD
binding, NADq binding, central, and interface do-
.mains and has 2 identical active sites composed of
specific amino acid residues from both subunits. Dur-
ing catalysis, electrons are sequentially transferred
from a dihydrolipoyl moiety bound to the substrate
protein to the redox disulfide in the E3 protein, the
FAD cofactor, and finally to NADq to generate
NADH.
Because E3 is the common component in these
complexes, lack of functional E3 causes reduction in
w xthe activities in PDC, KGDC, and BCKDC 1 . E3
deficiency leads to development of lactic acidosis and
neurological degeneration as well as elevated levels
of plasma branched-chain amino acids and urinary
excretion of the respective a-keto and a-hydroxy
w xacids 5 . E3 deficiency has been well documented in
w xat least 15 patients 6–15 , but specific mutations in
the coding region have been reported in only three
w xpatients 16–18 . In this paper, we report 2 additional
mutations, a deletion and a substitution, together
causing E3 deficiency and separately causing partial
deficiency in the heterozygous parents.
2. Clinical history
The proband was a male child who was the prod-
uct of a 42 week pregnancy, with a birth weight of
3.6 kg. He appeared normal after birth until the 3rd
day when he developed seizures, hypoventilation, and
circulatory failure associated with hepatomegaly, hy-
 .poglycemia, metabolic acidosis pH 7.05 , and ele-
 .vated lactate 12.8 mM, normal: 0.6–2.5 . He im-
proved with i.v. glucose, bicarbonate, and frequent
 .feeding. He then remained stable lactate 2–4 mM
until age 2 months when he was hospitalized again
for poor feeding and somnolence; his liver was not
enlarged at that time. He developed lactic acidosis
 .10–16 mM in the hospital while fasting. Serum
amino acid analysis showed increased alanine
 .1348 mM; normal: 132–455 , a-aminobutyrate
 . 106 mM; normal: 4–24 , leucine 300 mM; normal:
.  .61–183 , isoleucine 120 mM; normal: 27–80 , va-
 . line 345mM; normal: 78–142 , glycine 553 mM;
. normal 106–254 , threonine 236 mM; normal: 65–
.  .147 , methionine 151 mM; normal: 6–36 , and mildly
increased phenylalanine, cystathionine, cysteine, and
histidine. Urine organic acid analysis showed variable
increases of lactic, pyruvic, and a-keto- andror a-
hydroxy-isovaleric, isocaproic, butyric, and glutaric
acids, as well as succinic, adipic, suberic, and sebacic
acids. While on a low carbohydrate diet 17% of
.energy as CHO, 65% fat, 17% protein , blood lactate
 .was somewhat lower 4–6 mM . MRI of the head
 .age 19 months was normal. At age 15 months, his
 .  .length 50th%tile and weight 25th%tile were nor-
 .mal but his head was small 7th%tile . His develop-
 .ment was delayed DQs50–67 . He developed pro-
 .gressive optic atrophy. D,L-Lipoic acid 50 mgrkgrd
was administrated for 4 months without apparent
clinical or biochemical benefit. He died at age of 5
1r2 years following an acute illness. A limited au-
topsy was performed 2 h after death to obtain tissue
samples, which were frozen.
The mother became pregnant again following the
diagnosis of E3 deficiency in her son. Chorionic
villus sampling was performed at approximately 6
weeks of gestation; part of this sample was frozen
and assayed directly and another portion was cultured
for growth of fibroblasts. She gave birth to a healthy
female infant at 39 week gestation birth weight
.3.9 kg . There was no evidence in this child of any of
the clinical problems which had affected her elder
brother. Blood was obtained at birth from the umbili-
cal cord for isolation of lymphocytes, and again at
age 2 months; a skin biopsy was performed for
growth of fibroblasts. This child has remained in
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good health and is functioning normally at age of 7
years. The parents also have remained in good health
and are functioning at high intellectual levels.
3. Materials and methods
3.1. Cell and tissue samples and enzyme assays
All samples from human subjects were obtained
according to protocols approved by the Institutional
Review Board of University Hospitals of Cleveland,
with the informed consent of the parents of these two
children. Isolation of lymphocytes, culture of fibrob-
lasts, and assays of the activities of PDC, KGDC, and
w xE3 were performed as previously described 17,19,20 .
Control sample data were collected over several years
through the Center for Inherited Disorders of Energy
Metabolism, Case Western Reserve University, utiliz-
ing identical methods of sample collection and assays
to those used for the results shown here; concurrent
control samples were run with each assay.
3.2. Immunoblotting
14 mg of mitochondrial protein obtained from cul-
tured fibroblasts of a normal control, the proband and
his two parents were run on 12% sodium dodecyl
 .sulphate SDS polyacrylamide gel electrophoresis.
The proteins were transferred to a nitrocellulose
membrane using an electroblotting apparatus at 100 V
for 1 h, and immunoblotting was done as previously
w xdescribed 17 . The E3 immunospecific bands were
detected by E3 specific antibody raised against
 .porcine E3 and by chemiluminescence Du Pont . As
a standard, 25 ng of highly purified human E3 was
included.
3.3. RNA blotting
Total RNA was extracted from cultured fibroblasts
of the patient and a control by the guanidium thio-
w xcyanate method 21 . 25mg of total RNA was sepa-
rated by electrophoresis in 0.8% agarose gel contain-
ing 50% formaldehyde and subsequently transferred
w xto a Genescreen membrane 22 . The blot was prehy-
X wbridized with 20 mM piperazine-N, N -bis 2-ethane-
xsulfonic acid , pH 6.4, 2 mM EDTA, 0.8 M NaCl,
50% formamide, and 100 mgrml salmon sperm DNA
at 428C overnight. The membrane was probed with a
X w32 x1.1 kb 5 fragment of E3 cDNA labeled with P -a-
w xdCTP by the random primer reaction 23 . The blot
was washed with 2=SSCr1% SDS, 1=SSCr0.1%
SDS, 0.1=SSCr0.1% SDS at 508C, air dried, and
autoradiographed.
3.4. Construction of E3 cDNAs and DNA sequencing
E3 cDNA was prepared by reverse transcription
 .and the polymerase chain reaction RT-PCR as pre-
w xviously described 17 . Total RNA was isolated from
cultured fibroblasts of a control, the proband, the
proband’s younger sister, and the proband’s parents
 .as well as a frozen chorionic villus sample 10 mg
obtained from the mother’s subsequent pregnancy,
using the ‘‘Perfect RNA’’ isolation kit 5 Prime to 3
.Prime . Reverse transcription was carried out for 1 h
at 438C in a 20 ml reaction mixture which contained
 .1 mg of total RNA, 1 mg of oligo d T primer,16
0.5 nmoles of dNTP mixture, 20 mM dithiothreitol,
and 1 unit of SuperScript II reverse transcriptase
 .Life Technologies , in the reaction buffer supplied
by the manufacturer. Using the oligo dT primed first
strand cDNAs as templates, E3 cDNAs for each
specimen were specifically amplified by PCR using a
 Xpair of primers sense, 5 -GCGCGCGGATCCG-
GAGGTGAAAGTATTGGCGG-3X ; antisense,
5X-GCGCGCGGATCCTCAAAAGTTGATTGATTT-
X.GCC-3 that generate BamHI restriction sites at both
w xends of the full-length E3 cDNA 17 . For the
proband’s E3 cDNA analysis, the amplified 1.5 kb
fragment was isolated from agarose gel, cut with
BamHI, and ligated with pBluescript SKq vector
digested with the same enzyme. After confirmation,
the recombinant pBluescript vector containing E3
cDNA was transformed into E. coli XL1-Blue com-
petent cells. Plasmids containing the appropriate size
DNA inserts were sequenced 4 times using Seque-
 .nase kit ver. 2.0 US Biochemicals , using 4 pairs of
overlapping primers and pBluescript primers for the
entire E3 cDNA. To confirm the proband’s mutations
and the inheritance of these mutations from the par-
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Table 1
E3, PDC and CS activities in cells from the familya
Subject Lymphocytes Fibroblasts
E3 PDC CS E3 PDC CS
Controls:
Mean 67 1.68 52 58 2.47 36.2
3–97%tile 43–109 0.9–3.0 26–99 19–95 1.2–4.7 21–57
n 316 476 154 224 286 192
bProband 6 0.22 59 2 0.30 17.4
% 9% 13% 113% 3% 12% 48%
bMother 41 2.14 91 22 0.76 15.9
% 61% 127% 175% 38% 31% 44%
bFather 38 2.18 66 13 0.61 17.0
% 57% 130% 127% 22% 25% 47%
bSister 26 1.30 48 15 0.70 17.0
% 39% 77% 92% 26% 28% 47%
a Activity expressed as nmolrminrmg protein and % mean of
 .controls. CSscitrate synthase .
b Each activity value shown is the average of from 4–12 replicate
assays.
nsnumber of tested samples.
ents, direct DNA sequencing was performed with
genomic DNAs of the proband and the parents in the
regions surrounding the mutations.
4. Results
4.1. Enzyme assays
Assays of E3 in fresh blood lymphocytes and
cultured skin fibroblasts from the proband were 9%
and 3% respectively of the mean activity of controls
 .Table 1 . In lymphocytes from his mother and fa-
Fig. 1. Western blot analysis of E3 from cultured skin fibroblasts
 .14 mg of mitochondrial proteins of control, the proband and his
 .parents. Lane 1, purified human E3 25 ng ; lane 2, control; lane
3, proband; lane 4, father; lane 5, mother. The minor band,
located under E3 band, appears to be E3 binding protein protein
. w xX 28 .
ther, E3 activities were 61% and 57% of controls,
respectively, and in skin fibroblasts, E3 activities
 .were 38% and 22% Table 1 . PDC activity was 13%
of controls in lymphocytes from the proband but was
not reduced in lymphocytes from the parents 127–
.130% . On the other hand, PDC activity was 12% of
controls in cultured skin fibroblasts from the proband
and well below the range of controls in fibroblasts
from the mother and father 31% and 25% respec-
.tively . Therefore, the effect of partial E3 deficiency
 .in the parents on PDC activity was more severe in
cultured fibroblasts than in fresh lymphocytes. The
activity of citrate synthase, used as an internal mito-
chondrial control, was about half of that in controls in
skin fibroblasts from the proband and both of his
 .parents Table 1 .
KGDC activity was also greatly reduced in skin
fibroblasts from the proband, corresponding to 6% of
 .controls Table 2 . The relatively low activities of
PDC and KGDC found in the proband’s E3 deficient
Table 2
E3, PDC and KGDC activities in cultured fibroblasts and postmortem tissues from probanda
Subject Fibroblasts Heart Skeletal Muscle Liver
E3 PDC KGDC E3 PDC KGDC E3 PDC KGDC E3 PDC KGDC
Controls:
Mean 58 2.47 2.2 412 13.5 8.2 120 2.95 2.86 163 2.13 2.21
3–97%tile 19–95 1.2–4.7 0.5–5.2 179–598 7.6–24 4.8–11.8 63–204 1.1–7.3 1.5–4.8 92–281 1.1–4.2 0.5–3.5
n 224 286 23 25 25 6 161 173 9 49 51 5
bProband 2 0.30 0.14 17.8 3 0.12 12.6 0.40 0.02 17 0.44 0.06
% 3% 12% 6% 4% 22% 1% 11% 14% 1% 10% 21% 3%
a Activity expressed as nmolrminrmg protein and % mean of controls.
b Each activity value shown is the average of from 2–8 replicates.
nsnumber of tested samples.
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Table 3
E3 and PDC activities in chorionic villus samplesa
Subject Chorionic villus homogenate Cultured chorionic villus fibroblasts
E3 PDC E3 PDC
Controls:
Mean 208 2.9 83 3.7
Range 154–302 1.2–6.3 67–98 2.2–5.9
n 5 14 5 12
bSister 93 2.7 53 2.7
% 45% 93% 64% 73%
a Activity expressed as nmolrminrmg protein and % mean of controls.
b Each activity value shown is the average of from 2–8 replicate assays.
nsnumber of tested samples.
cultured skin fibroblasts are consistent with other
tissues assayed. In heart, skeletal muscle, and liver
samples obtained very soon after death, E3 activity
was 4–11% of controls, PDC activity was 14–22%,
 .and KGDC activity was only 1–3% Table 2 . In all
cells and tissue samples assayed, the effect of E3
deficiency was greater on KGDC than on PDC.
4.2. Western and Northern blot analyses
The results of immunoblotting demonstrate that
there was no difference in the content of E3 in
cultured skin fibroblasts from the proband or his
 .parents compared to that of a control subject Fig. 1 .
Despite the loss of E3 activity, the level of expressed
E3 protein seems not to be changed in the proband
and his parents. Although immunoreactive E3 was
present in cultured skin fibroblasts, this was not the
case for postmortem liver, heart, or skeletal muscle
samples, in which no E3 was detectable by immuno-
 .blotting data not shown . The difference presumably
reflects the variable stability of this mutant form of
E3 in cultured cells vs. postmortem tissues, as ordi-
narily E3 is relatively stable postmortem.
RNA blot analysis showed double bands of E3
mRNAs which were 2.2 and 2.4 kb in size from both
the proband’s and control cells; there was no signifi-
cant difference in the intensity of these bands be-
 .tween the subjects results not shown . These find-
ings indicate that E3 deficiency was not caused by a
lack of E3 mRNA.
4.3. DNA sequencing of E3 cDNAs
Two mutations were found in separate clones of
the proband’s full-length E3 cDNA coding sequence
  ..Fig. 2 A . One allele of the patient’s E3, found in 7
separate clones, showed a 3 nucleotide deletion 455th
to 457th, AGG; third nucleotide of 100th codon for
threonine and first two nucleotides of the 101st codon
.for glycine of the normal E3 coding sequence result-
ing in the deletion of Gly101. The other allele of the
proband’s E3, found in 6 separate clones, had a
substitution of A for G T for C in the antisense
.sequence at the 1173rd nucleotide, which results in
 .substitution of the codon for Glu340 GAA with
 .Lys340 AAA . DNA sequencing of the proband’s
E3 cDNA was repeated 3 times for each RT-PCR
generated product, and 3 independent RT-PCR reac-
tions were performed to eliminate any possible Se-
quenase or polymerase error. In both the proband’s
Fig. 2. DNA sequencing analysis of cloned and genomic E3 DNAs from control and 5 subjects. Only areas with mutations are shown.
 .‘Allele 1’ and ‘Allele 2’ are used to distinguish the two types of cloned E3 cDNAs, based on DNA sequencing. A Comparison of DNA
sequences of cloned E3 cDNAs around the mutation between a control and the proband. Deleted nucleotides are designated with a solid
 .bar. The substituted nucleotide in the proband is shown with an arrow. B Direct genomic DNA PCR sequencing of E3 gene from the
proband and his parents. Since a three nucleotide deletion mutation caused a frame shift of DNA sequences from both the proband and his
mother, overlapping sequences are shown in parts. For the substitution mutation found in both the proband and his father, only one
 .overlapping sequence is identified. C DNA sequencing data of cloned E3 cDNAs from a chorionic villus sample and cultured skin
fibroblasts from the proband’s sister compared with a control.
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and the mother’s genomic DNAs, direct sequencing
showed overlapping DNA sequences starting from
the 455th nucleotide caused by deletion of 3 nu-
cleotides in one of the two alleles, indicating that the
deletion mutation was inherited from the mother Fig.
 ..2 B . In direct sequencing of both the proband’s and
father’s genomic DNAs, both G and A C and T in
.the antisense sequence bands were found at the
1173rd nucleotide, demonstrating that the substitution
  ..mutation was inherited from the father Fig. 2 B .
4.4. Analysis of prenatal samples
Direct assay of E3 in a homogenate of the frozen
chorionic villus sample from the mother’s subsequent
pregnancy showed activity of 45% of controls, while
 .PDC activity was 93% Table 3 . Later, fibroblasts
cultured from this chorionic villus sample were as-
sayed and showed E3 and PDC activities equivalent
 .to 64% and 73% of controls, respectively Table 3 .
In lymphocytes obtained from cord blood and at age
2 months, E3 was 39% of controls, whereas PDC
 .activity was normal 77% of controls , while in cul-
tured skin fibroblasts from this child, E3 activity was
26% of controls and PDC activity was 28% Table
.1 . These assays of E3 activity in samples from the
daughter are consistent with a heterozygous condi-
tion. The difference between the consequences of
reduced E3 activity on PDC in lymphocytes and
fibroblasts is similar to what was found in the par-
ents. Citrate synthase activity was also lower in
fibroblasts.
Mutational analysis of cloned E3 cDNA prepared
from the frozen chorionic villus sample showed the
same deletion mutation as found in the mother’s E3
missing 3 nucleotides AGG, from 455th to 457th,
.   ..resulting in the deletion of Gly101 Fig. 2 C . This
mutation was also confirmed in E3 cDNA from
  ..cultured skin fibroblasts from the sister Fig. 2 C .
5. Discussion
The severe clinical consequences in this child with
a fatal form of E3 deficiency have been described in
most of the other reported cases of this disorder
w x6–12,24,25 . While there is considerable clinical
 .and probably genetic heterogeneity within this small
population, the predominant phenotypic conse-
quences are neurological, including impaired mental
development, seizures, and degenerative deterioration
w x26 . The predictable metabolic manifestations of in-
creased lactic, pyruvic, a-ketoglutaric, and
branched-chain a-keto and a-hydroxy organic acids
were all present, but the metabolic findings in this
case were complex, which also has been true for
other cases of E3 deficiency. In contrast to one
previous case who appeared to benefit from adminis-
w xtration of D,L-lipoic acid 9 , there was no evidence
for a beneficial effect of use of this agent in the
present case.
The partial reduction of E3 activity in the het-
erozygous parents and sister has a less severe effect
on PDC activity in blood lymphocytes or the chori-
onic villus sample than in cultured fibroblasts. Reduc-
tion of PDC activity has been observed previously in
w xskin fibroblasts from E3 heterozygotes 17,27 . This
difference may be due to the normally higher ratios
 .of E3 to PDC activity in lymphocytes 40:1 and
 .  .chorionic villus 72:1 than in fibroblasts 23:1 . The
lack of excess E3 in fibroblasts may be related to the
observation that citrate synthase is also lower in these
deficient and heterozygous cells, but the mechanism
is not known.
In this paper, we have identified two new muta-
tions, a 3 base pair deletion and a base substitution,
in the E3-deficient male proband. These two muta-
tions are located on different alleles. These mutations
are significant because they affect the catalytic func-
tion of the E3 protein without affecting its content
 .Fig. 1 or the content of E3 mRNA in cultured skin
fibroblasts. We found the mutations were inherited
from heterozygous parents. Those findings depended
on systematic characterization of full-length E3 cD-
NAs generated by RT-PCR from RNA isolated from
cultured fibroblasts. DNA sequencing data and signif-
icantly reduced activities of E3, PDC and KGDC in
the patient as well as a moderate reduction in the
parent’s cells confirm that these mutations were in-
herited from the parents in an autosomal recessive
 .manner Table 1 .
The mutations found in this patient, which affect
conserved amino acids, are located in the a-helixes
 .of the FAD domain Gly101del and the central
 .domain Glu340Lys , based on amino acid homology
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 .among E3s from various species Fig. 3 . The dele-
 .tion mutation inherited from the mother Gly101 ,
located within the highly conserved amino acid
residues of the 3rd a-helix of the FAD binding
domain, probably causes a regional structural change
which may affect the binding of FAD, resulting in the
loss of E3 activity. Glycine, a small, non-polar
residue, is not likely to be involved in inter-side chain
 .relationships. The substitution mutation Glu340Lys ,
inherited from the father, replaces a smaller, nega-
tively charged side chain of an amino acid in a
conserved a-helix with a bulky, positively charged
side chain. Since Glu340 is located in the hydrophilic
 .side of the a-helix Fig. 3 , this reversal in charge of
the side chain would be expected to exert more effect
on E3 activity than a local structural change due to
the size difference between the two amino acids.
Reduced E3 activity in fibroblasts from the father
indicates that this substitution mutation causes a sig-
 .nificant reduction about 50% of E3 activity. Based
on the available X-ray crystal structure of E3 from
w xthree prokaryotic sources 29–31 , it is not possible
to discern the functions of these two amino acids in
human E3 at the present time. The characterization of
overexpressed recombinant mutant E3s would shed
light on the possible roles of these two amino acids in
human E3.
The heterozygous status of the proband’s sister
was detected in utero by assay of E3 activity in a
chorionic villus sample and confirmed at birth in cord
blood lymphocytes, as well as cultured fibroblasts
from the chorionic villus and skin biopsies. To our
knowledge, this is the first reported example of suc-
cessful prenatal diagnostic testing for E3 deficiency.
 .Fig. 3. Regional homology of E3 in the area of mutations and the pictorial representation of potential a-helical structures. A Amino acid
 .sequence comparison of the area around two mutations in highly conserved regions, one Gly101del in the FAD binding domain and the
 .other Glu340Lys in the central domain from various species. Arrows designate the site of mutations. An asterisk represents deletion of
 .an amino acid Gly101 . The numbers on the right side of the amino acid sequences represent the locations of the first and last amino acid
w x w x w x w xresidues in the sequences. References for these sequences are: P. fluorescens, 29 ; P. putida, 30 ; A. ˝inelandii, 31 ; E. coli, 32 ; S.
w x w x w x w x  .  .cere˝isiae, 33 ; pig, 34 ; dog, 35 ; human, 4 ; E3-proband, this paper . B Pictorial representation, in the Edmundson wheel
projection, of the possible structures of two a-helices in which mutations were found. Only parts of the a-helices around the mutations
are shown. Arrows indicate the sites of mutations.
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After subsequently verifying the mutations present in
the proband and his parents, DNA from the chorionic
villus sample was analyzed and a single mutation was
identified; this was confirmed in the daughter’s cul-
tured skin fibroblasts. Although in this case muta-
tional analysis was done retrospectively, the same
analysis could be done prospectively for other cases,
if the two mutant alleles were characterized prior to
conception, and would provide definitive corrobora-
tion of assay of E3 activity.
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